TD Cowen analyst Yaron Werber reiterated a Buy rating on Roivant Sciences (NASDAQ: ROIV).The analyst commented, "New sub Pulmovant will ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE